Project BEST: Buprenorphine Entry Into Substance Abuse Treatment
NCT ID: NCT02583243
Last Updated: 2020-04-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
209 participants
OBSERVATIONAL
2005-05-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1
NCT00023283
Buprenorphine Maintenance for Opioid Addicts - 2
NCT00000203
A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence
NCT02718352
Buprenorphine Maintenance for Opioid Addicts - 1
NCT00000202
Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1
NCT00000216
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
GPRA, supplemental instrument, ASI, SCID, COWS, Urine toxicology.
Patients who are enrolled will enter a standardized, manual based weekly counseling regimen. Urine toxicology will be performed a minimum of twice monthly, but will not occur at the same times monthly to decrease the probability of sampling error.
This is a prospective cohort to follow a group of individuals on buprenorphine treatment. The goal of this prospective cohort is to generate thoughtful observations. Specific items of interest which will be compared with age, race matched historical controls on methadone will be:
1. Changes in addiction severity over treatment time
2. Changes in sexual risk behaviors and injection practices
3. Improvements in urine toxicology
4. Co-occurring mental illness
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MET/CBT based individualized counseling
Manualized counseling with the first four week being MET followed by 8 weeks of CBT
Buprenorphine
Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frederick L Altice, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University AIDS Program
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yale University
New Haven, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAMHSA TCE/HIV 15767
Identifier Type: -
Identifier Source: secondary_id
0504027630_B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.